Physician profile
John Sauret
NPI 1225000268
$5,558.25
in general payments reported to CMS, 2019-2025
32 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $282 · 2021: $502 · 2022: $669 · 2023: $1,018 · 2024: $1,299 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,498.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,161.45 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $929.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $596.07 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $428.61 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $352.31 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $315.17 | 2020-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $253.77 | 2019-2025 | Rybelsus, Ozempic |
| Shield Therapeutics INC | $191.25 | 2023-2025 | Accrufer |
| Mylan Specialty L.P. | $184.41 | 2019-2024 | Yupelri |
| Insulet Corporation | $145.01 | 2024-2025 | Omnipod |
| Amgen INC. | $128.72 | 2019-2025 | Repatha, Otezla, Repatha |
| Indivior INC. | $116.55 | 2023-2025 | Sublocade |
| Bayer Healthcare Pharmaceuticals INC. | $84.21 | 2021-2023 | |
| Gilead Sciences, INC. | $79.99 | 2021-2023 | |
| Mannkind Corporation | $76.97 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.70 | 2023-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $52.23 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $51.12 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $47.53 | 2024-2025 | |
| Abbott Laboratories | $39.00 | 2025 | Freestyle Libre 3 |
| Optinose US, INC. | $36.43 | 2024 | |
| Boston Scientific Corporation | $35.17 | 2023 | Watchman Access System |
| Phathom Pharmaceuticals, INC. | $29.22 | 2025 | Voquezna |
| Metacel Pharmaceuticals LLC | $27.09 | 2025 | Ozobax |
| Grifols USA, LLC | $24.67 | 2024 | Prolastin-C Liquid |
| Phadia US INC. | $24.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.30 | 2024 | Keveyis |
| Vanda Pharmaceuticals INC. | $16.21 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.01 | 2019 | |
| Philips North America LLC | $14.58 | 2019 | |
| Abbvie INC. | $12.93 | 2023 | Ubrelvy |
| Advanced Oxygen Therapy INC. | $8.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sauret listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.